As the number and diversity of targeted therapy approvals continue to rapidly increase, timely biomarker testing is now essential for making informed oncology treatment decisions. However, legacy testing approaches often fall short of clinical demands, especially for cases when rapid turnaround times (TAT) [ES1] are essential. This is particularly true for liquid biopsy applications and urgent single-gene screening scenarios, where delayed results can directly impact patient outcomes and treatment planning. Additionally, for many laboratories, the need to reduce TAT is driving a shift toward implementing in-house next-generation sequencing (NGS) solutions rather than outsourcing their testing to third-party labs.
In this Inside Precision Medicine webinar, our expert speakers will discuss how in-house NGS workflows overcome clinical and operational challenges including issues with tissue quantity, testing capacity, and TAT. The webinar will include case studies that illustrate how labs can implement Illumina’s sequencing technology internally to meet oncologists’ needs more effectively, and highlight benefits such as improved outcomes, faster reporting, and better alignment with clinical timelines. The session will also touch on how rapid targeted testing can complement broader genomic profiling and serve as a practical first step for implementing NGS capabilities in-house. Key takeaways from the webinar include:
- How NGS solutions address shortcomings from legacy technology and better serve the needs of local oncologists
- The advantages of NGS over current testing modalities such as PCR
- Why in-house testing makes sense for various testing modalities including liquid biopsy, heme testing, and more
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.
Produced with support from:
